MP09-20 THE COMBINATION OF HISTOLOGICAL PROSTATE ATROPHY AND INFLAMMATION IS ASSOCIATED WITH LOWER RISK OF PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II1 Apr 2016MP09-20 THE COMBINATION OF HISTOLOGICAL PROSTATE ATROPHY AND INFLAMMATION IS ASSOCIATED WITH LOWER RISK OF PROSTATE CANCER Daniel Moreira, J. Curtis Nickel, Gerald Andriole, Ramiro Castro-Santamaria, and Stephen Freedland Daniel MoreiraDaniel Moreira More articles by this author , J. Curtis NickelJ. Curtis Nickel More articles by this author , Gerald AndrioleGerald Andriole More articles by this author , Ramiro Castro-SantamariaRamiro Castro-Santamaria More articles by this author , and Stephen FreedlandStephen Freedland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2307AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Studies evaluating prostate atrophy and inflammation in benign biopsies have shown these histological findings are independently associated with lower prostate cancer (PCa) risk in subsequent biopsies. However, it is unclear how the presence of both atrophy and inflammation in the same negative biopsy modify the risk of subsequent PCa detection. Moreover, how the topographical association of atrophy and inflammation relates to PCa risk remains unknown. We evaluated whether the presence of both atrophy and chronic inflammation in the same biopsy and in the same biopsy core are associated with the risk PCa in repeat biopsies. METHODS We performed a retrospective analysis of 6307 men 50-75 years-old undergoing a 2-year repeat prostate biopsy after a negative baseline prostate biopsy for cancer in the Reduction by Dutasteride of PCa Events (REDUCE) study. Prostate atrophy, chronic inflammation, and cancer status (all coded as present or absent) were determined by central pathology. The association of baseline inflammation and atrophy (in the same biopsy and in the same biopsy core) with 2-year repeat biopsy cancer status was evaluated with chi-square test and logistic regression controlling for age, race, body-mass index, digital rectal exam, prostate volume, baseline biopsy PSA, family history of PCa, number of cores with atrophy and chronic inflammation and treatment arm (dutasteride or placebo). RESULTS Atrophy, inflammation and both were detected in 605 (10%), 1088 (17%) and 3785 (60%) baseline biopsies, respectively. Presence of atrophy was associated with presence of inflammation (P<0.001). Compared to biopsies with neither atrophy nor inflammation, presence of atrophy (OR=0.75, P=0.02), inflammation (OR=0.71, P=0.001) and both (OR=0.54, P<0.001) were associated with lower PCa risk in the 2-year repeat prostate biopsy. Results were similar in multivariable analysis (atrophy OR=0.79, P=0.08; inflammation OR=0.71, P=0.003 and both OR=0.63, P<0.001). Among men with both atrophy and inflammation in baseline biopsies, those with both findings in the same biopsy core had even lower PCa risk compared to men with atrophy and inflammation in different cores (univariable OR=0.67, P=0.007; multivariable OR=0.73, P=0.04). CONCLUSIONS In a cohort of men undergoing repeat prostate biopsy, the presence of both atrophy and inflammation in the baseline biopsy, especially in the same biopsy core, was associated with lower PCa risk. The presence and topographical distribution of prostate atrophy and inflammation may be used in PCa risk stratification. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e101 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Daniel Moreira More articles by this author J. Curtis Nickel More articles by this author Gerald Andriole More articles by this author Ramiro Castro-Santamaria More articles by this author Stephen Freedland More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...